Case of Severe Cardiotoxicity in a Pediatric Patient After Fluorouracil Administration.

[1]  R. Geller,et al.  The successful treatment of 5-fluorouracil (5-FU) overdose in a patient with malignancy and HIV/AIDS with uridine triacetate. , 2017, The American journal of emergency medicine.

[2]  M. Fakih,et al.  Emergency use of uridine triacetate for the prevention and treatment of life‐threatening 5‐fluorouracil and capecitabine toxicity , 2016, Cancer.

[3]  Jared M. Campbell,et al.  Fluoropyrimidine and platinum toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. , 2016, Pharmacogenomics.

[4]  Kirsten Vistisen,et al.  Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. , 2013, Cancer treatment reviews.

[5]  A. Frigo,et al.  Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer , 2009, British Journal of Cancer.

[6]  M. Saif,et al.  Fluoropyrimidine-associated cardiotoxicity: revisited , 2009 .

[7]  V. Catalano,et al.  Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy , 2008, The Pharmacogenomics Journal.

[8]  A. V. van Kuilenburg,et al.  High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. , 2002, Pharmacogenetics.

[9]  A. Fandi,et al.  Biology and treatment of nasopharyngeal cancer , 1995, Current opinion in oncology.

[10]  D. Keefe,et al.  Clinical Cardiotoxicity of 5‐Fluorouracil , 1993, Journal of clinical pharmacology.